Precision of maximum likelihood estimation in adaptive designs.

Area of Science:

• Biostatistics
• Clinical Trial Design
• Statistical Inference

Background:

• Adaptive clinical trial designs are gaining traction, allowing for modifications like sample size reassessment and treatment selection during interim analyses.
• Ignoring the complexities of adaptive designs and multiplicity can inflate type 1 error rates and bias treatment effect estimates derived from maximum likelihood principles.

Purpose of the Study:

• To investigate the behavior of maximum likelihood estimates (MLE) in adaptive clinical trial designs where adaptation rules are not fully specified in advance.
• To understand the bias and mean squared error (MSE) of MLE under various sample size reassessment and treatment selection rules.

Main Methods:

• The study examines adaptive designs starting with k treatment groups and a control, incorporating interim treatment selection and sample size reassessment.
• It analyzes both unlimited and realistically restricted sample size reassessment rules to understand their impact on bias and MSE.
• The research identifies sample size reassessment and selection rules that maximize bias or MSE, and explores constraints to mitigate overestimation.

Main Results:

• The investigation of bias and MSE is complicated by potentially unknown adaptation rules.
• Identifying rules that maximize bias or MSE generally leads to overestimation, which can be reduced by imposing practical constraints like a maximum sample size.
• The study considers various scenarios of sample size reassessments, from unlimited to restricted rules.

Conclusions:

• Understanding the behavior of MLE in adaptive designs is crucial, especially when adaptation rules are not fixed beforehand.
• Imposing realistic constraints on adaptive rules, such as maximum sample size, can help manage and reduce bias and MSE.
• The findings provide insights into parameter estimation challenges in flexible clinical trial designs.